Powered by
DETROIT–ID Ventures, the venture capital arm of Invest Detroit, the non-profit that supports business and real estate projects in the city and region, announced that it has been selected by …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …
LANSING–From gamified science learning to empowering youth athletes, entrepreneurs of all kinds joined the Lansing Economic Area Partnership (LEAP) and the greater Lansing community on Nov. 20 for the Hatching …
ANN ARBOR—Phenomics Health Inc., a University of Michigan research spinout that aims to increase the precision of pharmaceuticals by using individual people’s genetic information, announced it acquired patented pharmacometabolomic technology …
ANN ARBOR—Millendo Therapeutics Inc., (Nasdaq: MLND), a clinical-stage pharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, provided a corporate update and reported …
LANSING—Empowerment, community and sustainability are embedded within the Lansing region’s entrepreneurial ecosystem—values which were clearly visible during the Lansing Economic Area Partnership’s Sept. 26 Hatching business pitch competition, where three …
ROYAL OAK—OncoCell MDx Inc., a startup incubated at Harvard University to develop sophisticated cancer diagnosis from a simple blood sample, announced that it has raised $22.2 million in a Preferred …
GRAND RAPIDS—The Grand Rapids-based pharmaceutical startup Tetra Therapeutics announced that new preclinical research suggests the ability of its investigational drug, BPN14770, to protect against memory loss and neuronal atrophy induced …
DETROIT—Henry Ford Innovations, the health care technology commercialization arm of Henry Ford Health System, announced an exclusive licensing agreement with a Detroit software and health care company to market software …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor-based developer of a new class of cholesterol-reducing drugs, announced that the compensation committee of its board of directors granted non-qualified stock …